MET and neoplasm: Given the close association of CD151 with oncogenic drivers including growth factors, such as EGFR (Yang et al., 2008; Deng et al., 2012), HER2 (Yang et al., 2010; Deng et al., 2012; Romanska et al., 2015), and HGFR (c-Met) (Klosek et al., 2005; Franco et al., 2010; Ha et al., 2014), CD151 was shown to impair growth factor receptor-dependent processes such as tumor onset, cell growth, spreading and motility.